AdAlta Ltd (ASX: 1AD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

AdAlta Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $11.21 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 606.21 million
Earnings per share -0.013
Dividend per share N/A
Year To Date Return -16.67%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • AdAlta Ltd (ASX: 1AD)
    Latest News

    Woman thinking in a supermarket.
    Consumer Staples & Discretionary Shares

    Up 19% in 2024, is it time to buy or sell Coles shares?

    Let's see the verdict.

    Read more »

    woman in lab coat conducting testing representing biotech
    Share Market News

    AdAlta (ASX:1AD) share price rockets 31% on United States FDA update

    The AdAlta Ltd (ASX:1AD) share price is rocketing today following the positive news on its drug trials. Here's all the…

    Read more »

    1AD ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About AdAlta Ltd

    AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation protein and cell-based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.

    1AD Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    01 Nov 2024 $0.02 $0.00 0.00% 30,000 $0.02 $0.02 $0.02
    29 Oct 2024 $0.02 $0.00 0.00% 90,057 $0.02 $0.02 $0.02
    28 Oct 2024 $0.02 $0.00 0.00% 334,310 $0.02 $0.02 $0.02
    25 Oct 2024 $0.02 $0.00 0.00% 429,850 $0.02 $0.02 $0.02
    24 Oct 2024 $0.02 $0.00 0.00% 402,631 $0.02 $0.02 $0.02
    23 Oct 2024 $0.02 $0.00 0.00% 1,087,182 $0.02 $0.02 $0.02
    22 Oct 2024 $0.02 $0.00 0.00% 852,119 $0.02 $0.02 $0.02
    21 Oct 2024 $0.02 $0.00 0.00% 25,966 $0.02 $0.02 $0.02
    18 Oct 2024 $0.02 $0.00 0.00% 594,000 $0.02 $0.02 $0.02
    17 Oct 2024 $0.02 $0.00 0.00% 52,952 $0.02 $0.02 $0.02
    16 Oct 2024 $0.02 $0.00 0.00% 549,705 $0.02 $0.02 $0.02
    15 Oct 2024 $0.02 $0.00 0.00% 90,000 $0.02 $0.02 $0.02
    14 Oct 2024 $0.02 $0.00 0.00% 114,138 $0.02 $0.02 $0.02
    11 Oct 2024 $0.02 $0.00 0.00% 1,058,586 $0.02 $0.02 $0.02
    10 Oct 2024 $0.02 $0.00 0.00% 1,518,696 $0.02 $0.02 $0.02
    09 Oct 2024 $0.02 $0.00 0.00% 352,681 $0.02 $0.02 $0.02
    08 Oct 2024 $0.02 $0.00 0.00% 213,462 $0.02 $0.02 $0.02
    07 Oct 2024 $0.02 $0.00 0.00% 4,087 $0.02 $0.02 $0.02

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    06 Sep 2024 Timothy Oldham Buy 100,000 $2,195
    On-market trade.
    19 Dec 2023 Robert Peach Issued 1,750,000 $22,092
    Issue of options. Black-Scholes valuation
    19 Dec 2023 David Fuller Issued 1,750,000 $22,092
    Issue of options. Black-Scholes valuation
    19 Dec 2023 Paul MacLeman Issued 2,800,000 $35,347
    Issue of options. Black-Scholes valuation, typo error
    19 Dec 2023 Timothy Oldham Issued 500,000 $10,000
    Issue of securities.
    19 Dec 2023 Timothy Oldham Issued 500,000 $12,500
    Issue of options.
    19 Dec 2023 Timothy Oldham Issued 5,600,000 $70,694
    Issue of options. Black-Scholes valuation

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr David Fuller Non-Executive Director Jul 2020
    Dr Fuller has over 30 years of experience in pre-clinical, clinical development, medical and regulatory affairs with specialisations in early phase development and oncology.
    Dr Paul MacLeman Non-Executive ChairmanNon-Executive Director Oct 2019
    Dr MacLeman has expertise in capital management, business development, technology commercialisation and sales & marketing globally.
    Dr Timothy Oldham Managing DirectorChief Executive Officer Oct 2019
    Dr Oldham has more than 20 years of life sciences business development, alliance management, portfolio and product development, and commercialisation experience in Europe, Asia and Australia, with a particular focus on biologics, cell and gene therapies and pharmaceutical products.
    Dr Robert Peach Non-Executive Director Nov 2016
    Dr Peach has 30 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry.
    Mr Cameron Jones Chief Financial OfficerCompany Secretary May 2017
    -
    Cameron Jones Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Sacavic Pty Ltd <Morris Super Fund A/C> 97,441,722 16.36%
    HSBC Custody Nominees (Australia) Limited 85,720,663 14.39%
    Fletcher Meurs Investments Pty Ltd 27,029,924 4.54%
    YCLP Pty Ltd <Yclp A/C> 27,029,924 4.54%
    Radiata Foundation Ltd 20,560,519 3.45%
    Meurs Holdings Pty Ltd <P&M Meurs Superannuation A/C> 20,123,655 3.38%
    Skiptan Pty Ltd <P&M Meurs Family A/C> 19,407,256 3.26%
    Mr Tzu Hsuan Tseng 9,893,171 1.66%
    BNP Paribas Nominees Pty Ltd <HUB24 Custodial Serv Ltd> 7,058,296 1.19%
    Mr Craig Graeme Chapman <Nampac Discretionary A/C> 5,000,000 0.84%
    Scintilla Strategic Investments Limited 5,000,000 0.84%
    Mr John Okroglic 4,693,397 0.79%
    Citycastle Pty Ltd 4,302,320 0.72%
    Azzurra Investments Pty Ltd 4,050,000 0.68%
    Mr Kevin John Cairns & Mrs Catherine Valerie Cairns <Cairns Family Super A/C> 4,000,000 0.67%
    Mr Alistair David Strong 4,000,000 0.67%
    Mr David John Robinson 3,833,000 0.64%
    Mrs Gwen Murray Pfleger <Pfleger Family A/C> 3,600,000 0.60%
    Mr Peera Maytha 3,600,000 0.60%
    Castle Manor Pty Ltd <Arrendene Holdings A/C> 3,503,904 0.59%
    Huon Pine Pty Ltd <Huon Pine Investment A/C> 3,250,000 0.55%
    La Trobe University 3,041,330 0.51%
    Mr Michael Peter Hetrelezis <Mike'S Investment A/C> 3,000,000 0.50%
    Mr Kalpesh Varsani & Mrs Rita Varsani <Varsani Family S/F A/C> 3,000,000 0.50%
    Andrew P O'Brien Holdings Pty Ltd <Andrew P O'Brien A/C> 2,944,445 0.49%

    Profile

    since

    Note